

## PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1  
 Stylesheet Version v1.2

EPAS ID: PAT5448420

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT	
<b>NATURE OF CONVEYANCE:</b>	ASSIGNMENT	
<b>CONVEYING PARTY DATA</b>		
	<b>Name</b>	<b>Execution Date</b>
	TAKEDA PHARMACEUTICAL COMPANY LIMITED	04/24/2017
<b>RECEIVING PARTY DATA</b>		
<b>Name:</b>	MILLENNIUM PHARMACEUTICALS, INC.	
<b>Street Address:</b>	40 LANDSDOWNE STREET	
<b>City:</b>	CAMBRIDGE	
<b>State/Country:</b>	MASSACHUSETTS	
<b>Postal Code:</b>	02139	
<b>PROPERTY NUMBERS Total: 1</b>		
	<b>Property Type</b>	<b>Number</b>
	Application Number:	16098572
<b>CORRESPONDENCE DATA</b>		
<b>Fax Number:</b>	(617)535-3800	
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>		
<b>Phone:</b>	617-535-4453	
<b>Email:</b>	CHEATH@MWE.COM	
<b>Correspondent Name:</b>	KRISTIN A. CONNARN	
<b>Address Line 1:</b>	MCDERMOTT, WILL & EMERY, LLP	
<b>Address Line 2:</b>	500 NORTH CAPITOL STREET, N.W.	
<b>Address Line 4:</b>	WASHINGTON, D.C. 20001-1531	
<b>ATTORNEY DOCKET NUMBER:</b>	079259-0873	
<b>NAME OF SUBMITTER:</b>	KRISTIN A. CONNARN	
<b>SIGNATURE:</b>	/Kristin A. Connarn/	
<b>DATE SIGNED:</b>	03/29/2019	
<b>Total Attachments: 3</b>		
source=079259_0873_TAKEDA PHARMA TO MILLENNIUM PHARMA#page1.tif		
source=079259_0873_TAKEDA PHARMA TO MILLENNIUM PHARMA#page2.tif		
source=079259_0873_TAKEDA PHARMA TO MILLENNIUM PHARMA#page3.tif		

## ASSIGNMENT

WHEREAS, by virtue of agreement with and an Assignment from Takeda Pharmaceutical Company Limited (hereinafter "ASSIGNOR"), a Corporation having its principal place of business at **1-1, Doshomachi 4-chome, Chuo-ku, Osaka-Shi, Osaka, Japan 541-0045** has acquired an undivided interest in U.S. Patent Application No. **62/331,813** filed on **May 4, 2016**.

WHEREAS, Millennium Pharmaceuticals, Inc. (herinafter "ASSIGNEE"), having its principal place of business at **40 Landsdowne Street, Cambridge, Massachusetts 02139**, desires to acquire said undivided interest therein in accordance with agreements duly entered into with ASSIGNOR;

NOW, THEREFORE, in consideration of said Agreements and other good and sufficient consideration, the receipt of which is hereby acknowledged, Assignor has sold, assigned, transferred and set over, and by these presents do sell, assign, transfer and set over, unto Assignee, its successors, legal representatives and assigns, the right, title and interest in and to the above-mentioned inventions and application for Letters Patent, and in and to any and all direct and indirect divisions, continuations and continuations-in-part of said application, and any and all Letters Patent in the United States and all foreign countries which may be granted therefor and thereon, and reissues, reexaminations and extensions of said Letters Patent, and all rights under the International Convention for the Protection of Industrial Property, including all rights of priority, the same to be held and enjoyed by Assignee, for its own use and benefit and the use and benefit of its successors, legal representatives and assigns, to the full end of the term or terms for which Letters Patent may be granted and/or extended, as fully and entirely as the same would have been held and enjoyed by Assignor, had this sale and assignment not been made.

AND for the same consideration, Assignor hereby represents and warrants to Assignee, its successors, legal representatives and assigns, that, at the time of execution and delivery of these presents, except for any rights, titles and/or interests that have arisen to Assignee under law or that have already been transferred to Assignee and that the same are unencumbered and that

Assignor has good and full right and lawful authority to sell and convey the same in the manner herein set forth.

**AND** for the same consideration, Assignor hereby covenants and agrees to and with Assignee, its successors, legal representatives and assigns, that Assignor will sign all papers and documents, take all lawful oaths and do all acts necessary or required to be done for the procurement, maintenance, enforcement and defense of any Letters Patent and applications for Letters Patent for said inventions, without charge to Assignee, its successors, legal representatives and assigns, whenever counsel of Assignee, or counsel of its successors, legal representatives and assigns, shall advise: that any proceeding in connection with said inventions, or said Patent application for Letters Patent, or any proceeding in connection with any Letters Patent or applications for Letters Patent for said inventions in any country, including but not limited to interference proceedings, is lawful and desirable; or, that any division, continuation or continuation-in-part of any application for Letters Patent, or any reissue, reexamination or extension of any Letters Patent, to be obtained thereon, is lawful and desirable.

**AND** Assignor hereby requests the Commissioner of Patent and Trademarks to issue said Letters Patent of the United States to Assignee, as Assignee of said inventions and the Letters Patent to be issued thereon, for the sole use and benefit of Assignee, its successors, legal representatives and assigns.

**AND** Assignor hereby grants the following individuals the power to insert on this Assignment any further identification which may be necessary or desirable in order to comply with the rules of the United States Patent and Trademark Office for recordation of this document:

MCDERMOTT WILL & EMERY LLP


All practitioners at Customer Number 23630

**AND** Assignor acknowledge an obligation of assignment of this invention to Assignee at the time the invention was made.

IN TESTIMONY WHEREOF, ASSIGNOR by its duly authorized representative acting on its own free will has caused this instrument to be duly executed on the date set forth below.

SIGNED this 24 day of April, 2017.


**Takeda Pharmaceutical Company Limited**



Print Name: Hiroya Okumura

Print Title: Global Head of IP


Witness (1):



Print Name: SEIJI MORI

Print Title: Head of Operations (IP)

Witness (2):



Print Name: MAIKO HIRAI

Print Title: Director of Operations (IP)

Acknowledged and Accepted by:

**Millennium Pharmaceuticals, Inc.**



Print Name: Constance Yeung

Print Title: Associate General Counsel

DM\_US 81331363-1 079259 0765